Savara (SVRA) Shares Outstanding (Weighted Average) (2010 - 2026)

Savara (SVRA) reported Shares Outstanding (Weighted Average) of $253.3 million for Q1 2026, up 17.18% year-over-year from $216.1 million in Q1 2025, and up 13.89% on a QoQ basis from $222.4 million in Q4 2025.

Savara (SVRA) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $253.3 million in Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 17.18% year-over-year to $253.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $253.3 million (up 17.18% YoY) and the FY2025 annual result came in at $222.4 million, up 12.21% from the prior year.
  • Shares Outstanding (Weighted Average) climbed to $253.3 million in Q1 2026 per SVRA's latest filing, from $222.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $253.3 million in Q1 2026 and bottomed at $152.8 million in Q1 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $182.6 million (2024), against an average of $184.4 million.
  • The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) soared 98.42%; it then rose 0.0% in 2023.
  • Tracing SVRA's Shares Outstanding (Weighted Average) over 5 years: stood at $152.8 million in 2022, then gained by 8.14% to $165.2 million in 2023, then grew by 19.97% to $198.2 million in 2024, then grew by 12.21% to $222.4 million in 2025, then gained by 13.89% to $253.3 million in 2026.
  • Per Business Quant, the three latest SVRA Shares Outstanding (Weighted Average) figures stand at $253.3 million (Q1 2026), $222.4 million (Q4 2025), and $216.3 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Weighted Avg.) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 177,333.76 Bn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 185,491.37 Bn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 100.00 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 55.66 Bn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 118.76 Bn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 254.10 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - 16.04 Bn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 104.00 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 132.89 Mn
10 Savara 1.30 Bn 1.30 Bn - 253.28 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 253.28 Mn
Dec 31, 2025 222.39 Mn
Sep 30, 2025 216.35 Mn
Jun 30, 2025 216.29 Mn
Mar 31, 2025 216.15 Mn
Dec 31, 2024 198.19 Mn
Sep 30, 2024 211.85 Mn
Jun 30, 2024 182.57 Mn
Mar 31, 2024 182.55 Mn
Dec 31, 2023 165.20 Mn
Sep 30, 2023 152.78 Mn
Jun 30, 2023 152.78 Mn
Mar 31, 2023 152.78 Mn
Dec 31, 2022 152.77 Mn
Sep 30, 2022 152.77 Mn
Jun 30, 2022 152.77 Mn
Mar 31, 2022 152.77 Mn
Dec 31, 2021 133.92 Mn
Sep 30, 2021 152.59 Mn
Jun 30, 2021 114.93 Mn
Mar 31, 2021 76.99 Mn
Dec 31, 2020 59.31 Mn
Sep 30, 2020 60.29 Mn
Jun 30, 2020 58.86 Mn
Mar 31, 2020 57.36 Mn
Dec 31, 2019 40.03 Mn
Sep 30, 2019 38.75 Mn
Jun 30, 2019 38.44 Mn
Mar 31, 2019 36.02 Mn
Dec 31, 2018 33.30 Mn
Sep 30, 2018 34.48 Mn
Jun 30, 2018 31.43 Mn
Mar 31, 2018 31.32 Mn
Dec 31, 2017 17.52 Mn
Sep 30, 2017 24.21 Mn
Jun 30, 2017 13.81 Mn
Mar 31, 2017 3.03 Mn
Dec 31, 2016 1.96 Mn
Sep 30, 2016 1.60 Mn
Jun 30, 2016 1.04 Mn
Mar 31, 2016 2.54 Mn
Dec 31, 2015 968,810.00
Sep 30, 2015 163.61 Mn
Jun 30, 2015 162.13 Mn
Mar 31, 2015 159.46 Mn
Dec 31, 2014 122.41 Mn
Sep 30, 2014 123.29 Mn
Jun 30, 2014 115.59 Mn
Mar 31, 2014 105.05 Mn
Dec 31, 2013 102.71 Mn
Sep 30, 2013 102.71 Mn
Jun 30, 2013 53.75 Mn
Mar 31, 2013 46.27 Mn
Dec 31, 2012 47.64 Mn
Sep 30, 2012 47.72 Mn
Jun 30, 2012 47.72 Mn
Mar 31, 2012 47.72 Mn
Dec 31, 2011 37.09 Mn
Sep 30, 2011 26.47 Mn
Jun 30, 2011 26.25 Mn
Mar 31, 2011 22.76 Mn
Dec 31, 2010 13.18 Mn
Sep 30, 2010 14.70 Mn
Jun 30, 2010 11.52 Mn